LSL Pharma Group (TSXV:LSL) Research & Development: C$0.00 Mil (TTM As of Mar. 2026)


TSXV:LSL LSL Pharma Group Inc TSXV:LSL
49 GF Score
Price C$0.32
GF Value C$0.72
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is LSL Pharma Group Research & Development?

LSL Pharma Group TSXV:LSL 49 Research & Development is C$0.00 Mil as of Mar. 2026. GuruFocus rates TSXV:LSL with a GF Score™ of 49/100 and a GF Value™ of C$0.72 (Possible Value Trap). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. LSL Pharma Group's Research & Development for the three months ended in Mar. 2026 was C$0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was C$0.00 Mil.

LSL Pharma Group  (TSXV:LSL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

LSL Pharma Group Research & Development Related Terms

LSL Pharma Group Research & Development Historical Data

* Premium members only.

The historical data trend for LSL Pharma Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LSL Pharma Group Research & Development Chart

LSL Pharma Group Annual Data
Trend Sep20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 0.00 0.67 0.07 0.00 0.00

LSL Pharma Group Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSXV:LSL
49GF Score
LSL Pharma Group Inc TSXV:LSL
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LSL Pharma Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of C$0.00 Mil mean?
LSL Pharma Group (TSXV:LSL) has a Research & Development of C$0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on LSL Pharma Group and its competitors.
Is LSL Pharma Group's Research & Development too high?
LSL Pharma Group's current Research & Development is C$0.00 Mil. Overall, LSL Pharma Group has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does LSL Pharma Group's Research & Development compare to ZTS?
LSL Pharma Group's Research & Development of C$0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on LSL Pharma Group and its competitors. LSL Pharma Group's current Research & Development is C$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LSL Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, LSL Pharma Group (TSXV:LSL) is currently considered Possible Value Trap. The stock's GF Value™ is C$0.72, compared to a current price of C$0.32 — trading 55.6% below its estimated fair value. The current Research & Development is C$0.00 Mil. LSL Pharma Group's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For LSL Pharma Group (TSXV:LSL), the current Research & Development is C$0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is LSL Pharma Group (TSXV:LSL) Overvalued in 2026?

Based on GuruFocus' analysis, LSL Pharma Group stock appears to be undervalued. The current stock price of C$0.32 is trading 55.6% below its estimated GF Value™ of C$0.72. GuruFocus considers LSL Pharma Group to be Possible Value Trap.

Key valuation signals for TSXV:LSL:

  • Research & Development: C$0.00 Mil
  • GF Value™: C$0.72 vs. price of C$0.32 (55.6% below fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the TSXV:LSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

LSL Pharma Group Business Description

Address 540, rue d\'Avaugour, Bureau 1800, Boucherville, QC, CAN, J4B 0G6
LSL Pharma Group Inc develops, manufactures and commercializes sterile pharmaceutical products, cosmetic products and natural health products. It operates in three segments CMO activities include four operating entities LSL Laboratory, Dermolab, Du-Var, and VSI; Integrated Eye-care pharmaceutical company which includes sterile Eye-care manufacturing operation; and Private Label Business includes Juno OTC which commercializes pharmaceutical products with a focus on private label, over the counter (OTC) products. It derives majority of revenue from CMO activities segment.
49GF Score

Get the complete analysis for TSXV:LSL

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.32
Price
C$0.72
GF Value